LOS ANGELES--(BUSINESS WIRE)--Aug 31, 2023--

LOS ANGELES--(BUSINESS WIRE)--Aug 31, 2023--

ORLANDO, Fla.--(BUSINESS WIRE)--Aug 31, 2023--

SAN FRANCISCO--(BUSINESS WIRE)--Aug 31, 2023--

BESANÇON, France--(BUSINESS WIRE)--Aug 31, 2023--

Batteries in older Nissan Leaf electric vehicles are getting a new life as portable power sources that can be used to run gadgets on the go or deliver emergency power in disasters

Alcohol addiction ruins millions of lives every year, but scientists may have found a cure for this terrible affliction. A new treatment for alcohol use disorder (AUD) has been trialled in monkeys with impressive results and, if these translate to human trials, the impact could be monumental. A team of neuroscientists and physiologists from across the US tested a new type of gene therapy to see if they could directly target the underlying brain circuitry associated with sustained heavy drinking. As they noted, in the journal Nature Medicine, people suffering from AUD commonly return to alcohol use even if they attempt to quit. This is largely to do with what’s known as mesolimbic dopamine (DA) signalling – meaning how the central nervous system circuit communicates the feelgood neurotransmitter dopamine. A protein called glial-derived neurotrophic factor (GDNF) is key to keeping these neurons in this reward circuitry functioning. However, experts have found that levels of GDNF are reduced in people with AUD during periods of alcohol abstinence, most notably in a region of the brain called the ventral tegmental area (VTA), as IFLScience notes. Therefore, the researchers decided to test whether using gene therapy to deliver more GDNF to the VTA could help reinforce this crucial dopaminergic signalling and prevent patients from suffering an alcoholic relapse. The team of scientists explained how alcohol consumption in non-addicts prompts the release of dopamine, creating a pleasurable buzz feeling, but chronic alcohol use causes the brain to adapt and stop releasing so much dopamine. “So when people are addicted to alcohol, they don’t really feel more pleasure in drinking,” Dr Kathleen Grant, a senior co-author of the study, said in a statement. “It seems that they’re drinking more because they feel a need to maintain an intoxicated state.” For their research, Dr Grant and her colleagues used eight rhesus macaque monkeys, who were exposed to increasing concentrations of alcohol over four 30-day “induction” periods. The monkeys then had free access to alcohol and water for 21 hours a day for six months, during which they developed heavy drinking behaviours. This was then followed by a 12-week abstinence phase, with the GDNF treatment performed four weeks in for half of the subjects. The gene therapy was delivered using a a viral vector containing a copy of the human GDNF gene injected directly into the primate’s VTA, according to IFLScience. And the results were truly jaw-dropping. “Drinking went down to almost zero,” Dr Grant said. “For months on end, these animals would choose to drink water and just avoid drinking alcohol altogether. They decreased their drinking to the point that it was so low we didn’t record a blood-alcohol level.” The most exciting aspect of their findings is the suggestion that gene therapy could offer a permanent solution for people with the most severe cases of AUD. This will be a welcome glimmer of hope to many, given that some 29.5 million people were diagnosed with AUD in the US alone in 2021, according to the National Institute on Alcohol Abuse and Alcoholism. Of these 29.5 million sufferers, almost a million (894,000) were aged between 12 and 17. It’ll likely be some time before we know for sure whether the gene therapy can be rolled out in humans, but it’s an important first step in tackling this devastating disorder. Sign up for our free Indy100 weekly newsletter Have your say in our news democracy. Click the upvote icon at the top of the page to help raise this article through the indy100 rankings.

LOS ANGELES--(BUSINESS WIRE)--Aug 31, 2023--

A caterer who pretended to be a plastic surgeon has been arrested after performing a fatal penis enlargement on a 'patient'. Torben K, a 46-year-old man from Solingen, Germany, administered silicone injections into the victim's penis and scrotum area. He reportedly refused to disclose the type of silicone oil. The 32-year-old patient died from sepsis seven months after the procedure in July 2019. An investigation found that Torben had no medical qualifications and previously carried out the same procedure on another man earlier in the year. Judges in Wuppertal District Court found Torben guilty of causing death by grievous bodily harm. The sister of the unnamed victim said her brother had doubts about the treatment but Torben convinced him to go ahead. He was said to experience breathing difficulties as soon as he returned home. The man reportedly visited several hospitals but later died of blood poisoning and liver and kidney failure. Speaking to local media, High State Prosecutor Wolf-Tilman Baumert said: "Unfortunately, the silicone oil ended up in the person's bloodstream. This led to severe health complications and, eventually, to his death." Torben claimed he had only done what the patient requested, to which Baumert responded: "The fact that the man asked for the treatment is irrelevant from our point of view. The defendant acted in a highly immoral manner." Torben was jailed for five years, though the verdict is not yet legally binding. Sign up for our free Indy100 weekly newsletter Have your say in our news democracy. Click the upvote icon at the top of the page to help raise this article through the indy100 rankings.

BERLIN--(BUSINESS WIRE)--Aug 31, 2023--

Microsoft will allow business customers in Europe to buy its video and chat app Teams separately from its Office software, it said Thursday, a month after the European Union opened an antitrust investigation into the company's bundling of the products.

DUBAI, United Arab Emirates--(BUSINESS WIRE)--Aug 31, 2023--